BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using blood sampling
and communication of the results at 2 months, on adherence to monthly Bonviva (150mg po) in
women with post-menopausal osteoporosis. Patients will be randomized into either 1) a group
which receives bone marker feedback or 2)a group which does not receive feedback on the
results. The study will also assess patient satisfaction with treatment with once monthly
Bonviva. The anticipated time on study treatment is 3-12 months, and the target sample size
is 500+ individuals.